On the evening of January 13, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (300760. SZ) released the share repurchase plan of the company. The announcement showed that based on the confidence in the future development prospect and recognition of the internal value of the company, in order to safeguard the interests of investors and enhance investor confidence, in combination with the company’s operation, main business development prospect, financial status, future profitability and other factors, The company plans to use its own funds to buy back some of the company’s shares in the form of centralized competitive trading. The shares bought back will be cancelled and the registered capital will be reduced according to law.
According to the repurchase plan, the repurchase price does not exceed RMB 400 / share. Calculated by the upper limit of the repurchase price of RMB 400 / share and calculated by the repurchase amount of RMB 1 billion, the number of repurchased shares is expected to be 2.5 million shares, accounting for 0.2056% of the current total share capital of the company. The specific number of repurchased shares shall be subject to the actual number of repurchased shares at the end of the repurchase; The repurchase period shall not exceed 12 months from the date when the board of directors deliberates and approves the share repurchase plan.
Li Xiting, chairman of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) said: “this repurchase is precisely because we are firmly optimistic about the future development of the company and continue to be optimistic about the long-term value of Mindray. The ecology of China’s medical device industry is gradually prosperous, and the industry also has many new opportunities for development. While China’s medical devices go to the world, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) We will also continue to explore, actively carry out technological breakthroughs, contribute to the development of China’s medical device industry, and become a world leading medical device company. “
Prior to this, there was news on the Internet that Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) salespeople left their jobs, their performance did not meet expectations, and the inspection production line of Shanghai branch could not complete the task, which triggered a heated discussion. In this regard, Li Xiting said: “this rumor is sheer nonsense. In 2021, Mindray’s overall business performance was good and its personnel were stable. The performance of Shanghai branch increased well in 2021, with the completion of sales tasks exceeding 100%, a year-on-year increase of 46%, including the inspection line increasing by 53%.”
Market participants said that Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) repurchase of RMB 1 billion twice within half a year fully reflects the company’s management’s confidence in the future development of the company, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) is expected to seize the opportunity of the times and realize long-term and steady development.
In an interview with reporters, Li Xiting also said that at present, the company’s main business is growing steadily, and the emerging business continues to grow rapidly. Specifically, there are four important directions worthy of attention. First of all, IVD business growth accelerated, the promotion of four pillar new products of blood cell, biochemistry, luminescence and coagulation accelerated, the installation target improved, the international breakthrough of reagent business and the gradual increase of reagent sales; Secondly, the company will continue to support new medical infrastructure around the world. With excellent product performance, perfect multi product solutions and SanRui IT solutions, the company will seize good growth opportunities, continue to achieve breakthroughs and penetration of high-end hospitals, and expand brand influence; In addition, some orthopedic and IVD products benefited from the impact of centralized purchase, DRGs and other policies in some regions to accelerate the improvement of market coverage and share. In addition to the above three aspects, for emerging businesses with high potential, such as animal medicine, minimally invasive surgery, AED and orthopedics, the company will also increase R & D investment, accelerate the listing of new products and continue to achieve rapid growth.
